eligibility_summary
Eligible: ≥18 with advanced/metastatic CD70+ gynecologic cancer after failure/intolerance of standard therapy, measurable disease (RECIST 1.1), ECOG 0–2, >12‑week expectancy, adequate marrow/cardiac (LVEF ≥50%)/renal/hepatic/O2>92%, apheresis feasible, contraception, consent. Exclude: prior anti‑CD70, active CNS mets, recent trials/therapy/steroids/live vaccine, active infection, recent other cancers, major cardiac/autoimmune disease, active HBV/HCV/HIV/syphilis/CMV, significant VTE, uncontrolled HTN, pregnancy/breastfeeding, or otherwise unsuitable.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase I, parallel-arm trial of CD70-targeted CAR-T cells (autologous genetically engineered T-cell therapy) for CD70-positive advanced/metastatic gynecologic cancers (ovarian, cervical). Patients receive lymphodepletion with fludarabine (purine analog antimetabolite) and cyclophosphamide (alkylating agent), then CD70 CAR-T is administered intravenously or intraperitoneally at 1–10×10^6 cells/kg with 3+3 dose escalation and expansion. Mechanism: CAR bearing anti-CD70 scFv plus activation domains binds CD70 on tumor cells, triggering T-cell activation, cytokine release, and perforin/granzyme-mediated killing. Targets: CD70+ tumor cells, CD70/CD27 signaling axis, T-cell effector pathways.